Revolution Medicines (RVMD) is back in focus after reporting positive Phase 3 RASolute 302 results for daraxonrasib in metastatic pancreatic ductal adenocarcinoma, highlighted in a Plenary Session at the 2026 ASCO Annual Meeting.

The stock has been volatile but firmly upward over the past year, with a 30 day share price return of 12.02%, a 90 day move of 44.58% and a very large 1 year total shareholder return, as data readouts and new coverage have sharpened views on both opportunity and risk.

If this kind of oncology driven story has your attention, it can be useful to compare Revolution Medicines with other specialised healthcare AI opportunities through the 34 healthcare AI stocks.

With Revolution Medicines now valued at about US$32.2b and trading near a recent analyst price target, the key question is simple: are investors still underestimating its RAS pipeline, or is the stock already pricing in future growth?

Most Popular Narrative: 13.4% Overvalued

At a last close of $151.56 versus a narrative fair value of $133.70, the current price sits ahead of what the most followed model implies, and that view leans heavily on a very ambitious long term earnings profile.

The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.

Want to see what kind of revenue curve and margin uplift would need to sit behind this price tag? The narrative leans on rapid top line expansion, improving profitability and a rich future earnings multiple that few loss making biotechs command for long. Curious how those moving pieces combine into a single fair value path.

Result: Fair Value of $133.70 (OVERVALUED)

However, even this bullish setup bumps into real pressure points, including heavy 2026 operating expense guidance of US$1.6b to US$1.7b and concentrated RAS trial risk.

Another View: DCF Points the Other Way

While the most followed narrative tags Revolution Medicines as 13.4% overvalued versus its $133.70 fair value, the Simply Wall St DCF model paints a very different picture. In this view, the stock at $151.56 trades about 69.3% below an estimated future cash flow value of $492.88, raising the question of which set of assumptions you find more realistic.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revolution Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such different signals on valuation and a mix of concerns and potential upsides, it makes sense to look at the numbers yourself and move quickly to form a view that fits your risk tolerance, starting with the 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you risk missing opportunities that better fit your goals, time horizon and comfort with risk across different parts of the market.

• Broaden your opportunity set and compare quality across the market using the 48 high quality undervalued stocks.
• Prioritise resilience by reviewing companies that appear more defensively positioned through the 69 resilient stocks with low risk scores.
• Spot potential future standouts early by scanning the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.